Mitochondrial SIRT3: a new potential therapeutic target for metabolic syndrome.

ABSTRACT: In this issue of Molecular Cell, Hirschey et al. demonstrate that loss of the NAD(+)-dependent deacetylase SIRT3 and resultant mitochondrial protein hyperacetylation play a critical role in the pathogenesis of metabolic syndrome, providing new insights into the therapeutic potential of SIRT3.

SUBMITTER: Yoshino J 

PROVIDER: S-EPMC3215590 | biostudies-literature | 2011 Oct

REPOSITORIES: biostudies-literature